Literature DB >> 24321419

Risk factors for arterial thrombosis in antiphospholipid syndrome.

Aleksandra Matyja-Bednarczyk1, Jakub Swadźba1, Teresa Iwaniec1, Marek Sanak1, Sylwia Dziedzina1, Adam Ćmiel2, Jacek Musiał3.   

Abstract

INTRODUCTION: Antiphospholipid syndrome (APS) is associated with the risk of both arterial and venous thrombosis. However, it is not known which factors might determine the location of thrombosis.
MATERIALS AND METHODS: To retrospectively characterize factors associated with the risk of arterial thrombosis in a cohort of APS patients. Analysis included laboratory and clinical criteria of APS, together with classical cardiovascular risk factors and the possible role of platelet integrin α₂β₁ (807 C/T) and α(IIb)β₃ (PI A1/2) genetic polymorphisms. We enrolled 163 APS patients (123 women and 40 men aged 21-75; mean age 43 years); 78 suffered from arterial thrombosis.
RESULTS: There were no significant differences in the frequency or titers of different antiphospholipid antibodies with the exception of slightly increased frequency of IgG anticardiolipin antibodies (ACL) in the arterial thrombosis group. Livedo reticularis was observed significantly more often in the arterial thrombosis group, particularly in stroke patients. In univariate analysis arterial thrombosis was associated with male gender (OR-2,201; p=0,033), arterial hypertension (OR-2,81; p=0,002) and hypercholesterolemia (OR-3,69; p=0,001). On multivariate analysis arterial hypertension (OR=1,78; p=0,008) and hypercholesterolemia (OR=2,001; p=0,002) remained as independent risk factors for arterial thrombosis. Platelet glycoprotein polymorphisms studied did not show any significant associations with arterial thrombosis in APS patients.
CONCLUSIONS: Among APS patients those with ACL IgG antibodies, having livedo reticularis, and suffering from hypertension an hypercholesterolemia are at the increased risk of arterial thrombosis.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APA; APS; AT; Antiphospholipid antibodies; Antiphospholipid syndrome; Arterial thrombosis; CNS; Central Nervous System; DVT; LR; Livedo reticularis; Polymorphisms of the platelet integrins; RP; Raynaud's phenomenon; Risk factors for cardiovascular diseases; SAPS; SLE; Secondary Antiphospholipid syndrome, PAPS, Primary Antiphospholipid syndrome; Systemic Lupus Erythematosus, LA, lupus anticoagulant, DNA, Deoxyribonucleic acid; aCL; anticardiolipin; deep vein thrombosis; livedo reticularis

Mesh:

Substances:

Year:  2013        PMID: 24321419     DOI: 10.1016/j.thromres.2013.11.012

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  14 in total

Review 1.  Prevention of thrombosis in antiphospholipid syndrome.

Authors:  Wendy Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 2.  An Update on Antiphospholipid Syndrome.

Authors:  Eleni Xourgia; Maria G Tektonidou
Journal:  Curr Rheumatol Rep       Date:  2022-01-05       Impact factor: 4.592

Review 3.  Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?

Authors:  Kimberly Janet Legault; Amaia Ugarte; Mark Andrew Crowther; Guillermo Ruiz-Irastorza
Journal:  Curr Rheumatol Rep       Date:  2016-05       Impact factor: 4.592

Review 4.  Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

Authors:  Yu Zuo; Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2018-09-10       Impact factor: 4.592

5.  Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study.

Authors:  Hui Jiang; Chu-Han Wang; Nan Jiang; Jing Li; Chan-Yuan Wu; Qian Wang; Meng-Tao Li; Xin-Ping Tian; Jiu-Liang Zhao; Yan Zhao; Xiao-Feng Zeng
Journal:  Arthritis Res Ther       Date:  2021-05-08       Impact factor: 5.156

6.  IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients.

Authors:  Savino Sciascia; Irene Cecchi; Massimo Radin; Elena Rubini; Ana Suárez; Dario Roccatello; Javier Rodríguez-Carrio
Journal:  Front Med (Lausanne)       Date:  2019-09-26

Review 7.  VWF, Platelets and the Antiphospholipid Syndrome.

Authors:  Shengshi Huang; Marisa Ninivaggi; Walid Chayoua; Bas de Laat
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

8.  Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.

Authors:  Eleana Bolla; Nikolas Tentolouris; Petros P Sfikakis; Maria G Tektonidou
Journal:  Lupus Sci Med       Date:  2021-12

Review 9.  Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

Authors:  Malgorzata M Bala; Magdalena Celinska-Lowenhoff; Wojciech Szot; Agnieszka Padjas; Mateusz Kaczmarczyk; Mateusz J Swierz; Anetta Undas
Journal:  Cochrane Database Syst Rev       Date:  2017-10-02

10.  Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

Authors:  Malgorzata M Bala; Magdalena Celinska-Lowenhoff; Wojciech Szot; Agnieszka Padjas; Mateusz Kaczmarczyk; Mateusz J Swierz; Anetta Undas
Journal:  Cochrane Database Syst Rev       Date:  2020-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.